Kodiak Sciences Announces Closing of Initial Public Offering
On October 9, 2018, Kodiak Sciences Inc. (Kodiak), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced the closing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares began trading on the Nasdaq Global Market under the ticker symbol "KOD" on October 4, 2018. Wilson Sonsini Goodrich & Rosati is representing Kodiak in the offering.
Morgan Stanley and BofA Merrill Lynch acted as joint book-running managers for the offering. Barclays acted as a book-running manager for the offering. Chardan acted as lead manager.
For more information, please see Kodiak's press release.